Pfizer, Chevron, and AbbVie Set for Strong Dividend Growth in 2027

Pfizer, Chevron, and AbbVie are expected to continue their strong dividend returns in 2027. Pfizer aims to reach $35 per share by driving growth from its obesity and oncology products. Meanwhile, Chevron targets $250 per share supported by its Guyana projects and AI energy investments.

AbbVie looks to reach $325 fueled by robust sales of Skyrizi and Rinvoq. Each company maintains healthy dividends and growth strategies, but achieving these targets depends on continued execution and favorable market conditions.

Hedge funds have been buying Pfizer shares attracted by its 6.3% dividend yield and promising oncology drug pipeline. However, challenges from patent expirations could impact earnings.